Ensuring access to safe, effective, and affordable cannabis‐based medicines

Article highlights the challenge for regulators is that many patients want to use unapproved or non-standardised cannabis products to treat conditions where there is weak or no evidence. It describes advantages & disadvantages of different regulatory models allowing their use.

Source:

British Journal of Clinical Pharmacology